Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Total Non-Current Liabilities (2023 - 2025)

Kura Oncology (KURA) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $561.1 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 62.76% to $561.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $561.1 million through Dec 2025, up 62.76% year-over-year, with the annual reading at $561.1 million for FY2025, 62.76% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $561.1 million at Kura Oncology, up from $403.9 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $561.1 million in Q4 2025, with the low at $30.4 million in Q1 2023.
  • Average Total Non-Current Liabilities over 3 years is $197.5 million, with a median of $52.3 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities increased 23.87% in 2024, then soared 687.96% in 2025.
  • Over 3 years, Total Non-Current Liabilities stood at $51.0 million in 2023, then skyrocketed by 576.5% to $344.7 million in 2024, then skyrocketed by 62.76% to $561.1 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $561.1 million, $403.9 million, and $374.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.